Larazotide: Research & Studies

Research Overview#

Larazotide acetate has been evaluated in multiple clinical trials spanning Phase 1 through Phase 3, making it one of the most extensively studied investigational therapies for celiac disease. The clinical trajectory illustrates both the promise and challenges of developing treatments for celiac disease.

Phase 2a: Gluten Challenge Study (PMID 22825365)#

The Phase 2a study evaluated larazotide's ability to prevent celiac disease activation during controlled gluten challenge in 86 patients. The study demonstrated that larazotide reduced gluten-induced increases in intestinal permeability, providing proof-of-concept for the zonulin receptor antagonism mechanism.

Phase 2b: Persistent Symptoms Study (PMID 25683116)#

The pivotal Phase 2b trial (Kelly et al., 2015) evaluated three doses of larazotide (0.5, 1, 2 mg TID) versus placebo in 342 celiac patients with persistent symptoms despite adherence to a gluten-free diet. This was the first trial to use patient-reported symptom outcomes as the primary endpoint.

The 0.5 mg dose achieved statistical significance on the primary endpoint (symptom reduction vs placebo, P=0.022), with clinically meaningful improvements including 26% fewer symptomatic days and 31% more improved symptom days. The safety profile was comparable to placebo.

The unexpected inverted dose-response (lower dose more effective) was a notable finding. Hypotheses include: optimal receptor occupancy at lower concentrations, potential agonist activity at higher concentrations, or pharmacokinetic factors related to luminal drug distribution.

Phase 3: CeDLara Trial (Discontinued 2022)#

The Phase 3 CeDLara trial enrolled 525 patients across three arms (0.25 mg TID, 0.5 mg TID, placebo) for 24 weeks. In June 2022, 9 Meters Biopharma announced discontinuation after an interim analysis showed the treatment effect was insufficient relative to the placebo response to achieve significance with a feasible sample size.

Key factors in the Phase 3 failure:

• Strong placebo response: Celiac disease trials consistently show high placebo response rates on patient-reported outcomes
• Endpoint challenges: Symptom-based endpoints in celiac disease are inherently variable
• Population heterogeneity: Celiac patients on a gluten-free diet have variable levels of inadvertent gluten exposure and symptom severity

Evidence Quality Assessment#

Research Evidence Context#

Larazotide belongs to the Immune category of research peptides. The research evidence for Larazotide spans multiple study types and endpoints. Researchers should evaluate the strength of evidence based on study design, sample size, and publication status when drawing conclusions about efficacy and safety.

Key Clinical Studies#

The following studies provide the clinical evidence base for Larazotide:

Larazotide Acetate for Persistent Symptoms of Celiac Disease Despite a Gluten-Free Diet: A Randomized Controlled Trial#

Authors: Kelly CP, Green PH, Murray JA, et al. (2015) — Gastroenterology

Phase 2b multicenter RCT of larazotide acetate (0.5, 1, 2 mg TID) in 342 adults with celiac disease on a gluten-free diet for at least 12 months. The 0.5 mg dose significantly reduced symptoms compared to placebo.

Key Findings:

• 0.5 mg dose significantly reduced celiac symptoms vs placebo (P=0.022)
• 26% decrease in symptomatic days with 0.5 mg dose
• 31% increase in improved symptom days
• Safety profile comparable to placebo
• Higher doses (1 mg, 2 mg) did not show significance (inverted dose-response)

Limitations: Inverted dose-response not fully explained; patient-reported outcomes subject to placebo effect; no biomarker confirmation of tight junction effects

A Randomized, Double-Blind Study of Larazotide Acetate to Prevent the Activation of Celiac Disease During Gluten Challenge#

Authors: Kelly CP, Green PH, Murray JA, et al. (2013) — American Journal of Gastroenterology

Phase 2a study evaluating larazotide acetate during controlled gluten challenge in 86 celiac disease patients. Larazotide reduced intestinal permeability changes induced by gluten exposure.

Key Findings:

• Larazotide reduced gluten-induced changes in intestinal permeability
• Prevented the increase in lactulose/mannitol ratio during gluten challenge
• Well tolerated with safety comparable to placebo

Limitations: Small sample size (n=86); controlled gluten challenge not representative of real-world inadvertent exposure

Larazotide Acetate: A Pharmacological Peptide Approach to Tight Junction Regulation#

Authors: Gopalakrishnan S, Tripathi A, Tamiz AP, et al. (2021) — American Journal of Physiology - GI and Liver Physiology

Comprehensive review of larazotide acetate pharmacology including in vitro tight junction studies, in vivo permeability models, and clinical trial data synthesis.

Key Findings:

• Larazotide prevents opening of tight junctions induced by cytokines, bacterial agents, and gluten fragments in vitro
• Redistributes and rearranges tight junction proteins (ZO-1, claudins, occludin) and actin filaments
• Acts as a zonulin receptor antagonist with local gut action
• Minimal systemic absorption confirmed across studies

Limitations: Review article; Phase 3 results not available at time of publication

Evidence Quality Assessment#

The overall evidence level for Larazotide is classified as moderate. There is meaningful clinical evidence from Phase 2 or similar trials, though larger confirmatory studies may be needed.

Research Gaps and Future Directions#

The following gaps in the current evidence base for Larazotide have been identified:

• Understanding why Phase 3 failed despite positive Phase 2b results (placebo response, endpoint selection, dose optimization)
• Biomarker-confirmed mechanism of action in clinical settings (tight junction protein quantification in human biopsies during treatment)
• Potential applications in non-celiac conditions with intestinal permeability dysfunction (IBD, type 1 diabetes, IBS)
• Optimal dosing regimen (the inverted dose-response in Phase 2b suggests the dose-response relationship needs further characterization)
• Combination approaches with other celiac disease therapies (gluten-degrading enzymes, immune modulators)

Addressing these research gaps will be important for establishing a more complete understanding of Larazotide's therapeutic potential and safety profile.

Related Reading#

• Larazotide overview and research guide
• Larazotide dosing protocols
• Larazotide molecular structure